



Global Access Program

Bridging the care gap to accelerate **disease elimination** goals in low- & middle-income countries



Control and elimination of preventable diseases such as HIV, hepatitis, tuberculosis and cervical cancer rely on testing and diagnostics services. However, nearly half of the world's population has little or no access to diagnostics, which are critical to reducing premature deaths in low- and middle-income countries.

At Roche we are committed to working with partners to deliver sustainable and accessible diagnostic solutions across low- and low-middle income countries to meet global infectious disease elimination goals.


Lancet. 2021 27 November-3 December; 398(10315): 1997-2050.
Published online 2021 Oct 6. doi: 10.1016/S0140-6736(21)00673-5

Through the Roche Global Access Program, we support 89 countries across Africa, Latin America, Eastern Europe, Middle East, and Asia Pacific regions to enhance their ability to manage high-burden diseases like HIV, hepatitis B and C, tuberculosis and cervical cancer.


- The Roche Global Access Program focuses on three priorities:
 - Delivering excellence through capacity building, training healthcare workers and equipping labs to meet local needs while efficiently integrating testing across diseases.
 - Supporting ecosystems that create optimised networks for patients with appropriate, timely and cost-effective diagnostics services.
 - Ensuring sustainability by working with partners to ensure continual funding for diagnostics and reinforce the integral role partnerships play in strengthening health systems, achieving health goals, and improving health outcomes.



Global Access Program Timeline



Disease Prevalence: Deaths



Disease Elimination Goals

WHO Elimination Goals to set a direction and a vision
Targets to track reduction in the overall disease burden:

	2030	2030	2030	2030
HIV₂	95 Tested	95 Treated	95 Durable viral suppression	
Hep₃	90 Reduction in incident	65 Reduction in mortality	85 Treated	
TB₄	95 Reduction in mortality	90 Reduction in incidence	00 Affected families	
CxCas	90 Vaccinated	70 Screened	90 Treated	

Countries with Global Access Program

The program provides increased access to diagnostics at affordable pricing for eligible organizations in 89 eligible countries with the highest disease burden.



References:

1. <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> (accessed on 4 June 2026)
2. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b> (accessed on 4 June 2026)
3. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-c> (accessed on 4 June 2026)
4. <https://www.who.int/news-room/fact-sheets/detail/tuberculosis> (accessed on 4 June 2026)
5. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> (accessed on 4 June 2026)
6. Understanding Fast-Track. Accelerating Action to end the AIDS epidemic by 2030. https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf (accessed 4 June 2026)
7. <https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=AC1645C173756FB7A161689347064065?sequence=1> (accessed 4 June 2026)
8. The End TB Strategy 2022. Geneva: World Health Organization; 2022.
9. <https://www.who.int/news-room/fact-sheets/detail/cervical-cancer> (accessed on 4 June 2026)
10. <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality>. (accessed 4 June 2026)
11. Baker MG, Wilson N, Anglemeyer A. Successful Elimination of Covid-19 Transmission in New Zealand. *N Engl J Med* 2020;383:e56. 10.1056/NEJMc2025203

Roche Molecular Systems
4300 Hacienda Drive
Pleasanton, CA 94588 USA

<https://www.roche.com/about/strategy/access-to-healthcare/global-access-program>

